Company intelligence / Profile preview

Sinco Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Sinco distributes commercial-stage imported blood products with strong clinical demand in China. Its own R&D pipeline in medical aesthetics focuses on polycaprolactone-based injectables/devices, currently under development with safety assessments ongoing. No late-stage clinical data disclosed.

Therapeutic areas: HematologyGastroenterologyCardiovascularOther
Modalities: Biologic (blood products such as human albumin solution, immunoglobulins, coagulation factors)Small molecule (anti-infective drugs)Medical device/biomaterial-based therapy (polycaprolactone-based medical aesthetic products)
Industry: Therapeutic Medical Devices

Partnerships

Octapharmathird-party promotional service providers

Beyond the preview

Go deeper on Sinco Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinco Pharmaceuticals.

Explore the full profile